Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide ...

(Medical Xpress)—Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with ...

Researchers at Moffitt Cancer Center and colleagues from 11 other institutions in the United States and the United Kingdom have used two genome-wide association studies (GWAS)  one from the U.S. and one from the U.K. ...

Scientists at A*STAR's Institute of Medical Biology (IMB) and the Bioinformatics Institute (BII) have found new clues to early detection and personalised treatment of ovarian cancer, currently one of the most difficult cancers ...

(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to ...

Researchers at Case Western Reserve University have identified a microRNA biomarker that shows promise in predicting treatment response in the most common form of ovarian cancer – a breakthrough that has the potential to ...

Epithelial ovarian cancer is the most lethal cancer of the female reproductive organs, with more than 200,000 new cases and more than 125,000 deaths each year worldwide. Because symptoms tend to be vague, 80 percent of these ...